Fusion Antibodies interim revenue falls on-year but outlook optimistic
Fusion Antibodies PLC on Thursday said it remains on plans with its strategic goals as it anticipates a stronger second financial half.
The Belfast-based contract researcher that provides discovery, design and optimisation services for therapeutic antibodies reported revenue of £838,000 in the six months to September 30, its first financial half, down from £1.2 million a year earlier but up from £755,000 in the second half of financial 2025.
Gross margin improved to 30% from 22%, reflecting better operational efficiency.
Fusion expects a stronger second half supported by a solid order book and improved market sentiment.
The company highlighted a new US patent covering its OptiMAL library design, continued collaboration with the National Cancer Institute, and multiple new humanisation contracts. Cash as at September 30 stood at £251,000, in line with management expectations.
Chair Simon Douglas said: ‘Cash continues to be carefully managed and, as set out in the company’s financial 2025 results announced on 4 September 2025, based on internal estimates the company has a cash runway into financial 2027 and remains on plan with our strategic goals including the launch of OptiMAL in December which we believe will herald a new stage in the company’s development and open up new markets and revenues.’
Fusion Antibodies shares rose 4.9% to 13.90 pence each on Thursday afternoon in London.
Copyright 2025 Alliance News Ltd. All Rights Reserved.